title: [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
abstract: Bisphosphonate-related osteonecrosis of the jaw have been widely described. Denosumab has recently been associated to ONJ. Guidance to clinicians is based on criteria established by the American Association of Oral and Maxillofacial Surgeons (AAOMS). Treatment should be multidisciplinary. Two options are available and have to be discussed on the basis of associated therapeutic, patient's general state of health and possibility of therapeutic window during cancer treatment: conservative (medication and conservative surgery like superficial debridement) and extensive surgery. Therefore, we report an update about management strategies of osteonecrosis of the jaw and two cases of patients with a stage 2 osteonecrosis of the jaw only treated with mouth rinses, antibiotics and debridement and complete healing.
authors.affiliation: Centre Jean-Perrin, oncologie médicale, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Dupic
authors.affiliation: Centre Jean-Perrin, oncologie médicale, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: Denise
authors.initials: D
authors.lastname: Collangettes
authors.affiliation: Centre Jean-Perrin, oncologie médicale, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: Anne-Françoise
authors.initials: AF
authors.lastname: Dillies
authors.affiliation: Centre hospitalier universitaire Estaing, onco-hématologie, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France.
authors.forename: Laure
authors.initials: L
authors.lastname: Calvet
authors.affiliation: Centre hospitalier universitaire Estaing, onco-hématologie, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tournilhac
authors.affiliation: Centre Jean-Perrin, oncologie médicale, 58, rue Montalembert, 63000 Clermont-Ferrand, France; Centre hospitalier universitaire Estaing, onco-hématologie, 1, place Lucie-Aubrac, 63000 Clermont-Ferrand, France.
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.affiliation: Centre Jean-Perrin, oncologie médicale, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: Hakim
authors.initials: H
authors.lastname: Mahammedi
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000379:methods; D000069448:Denosumab / Q000009:adverse effects*; D005260:Female; D006304:Health Status; D006801:Humans; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab
keywords: Bisphosphonate; Bisphosphonates; Chirurgie; Conservative treatment; Denosumab; Guidelines; Management strategies; Osteonecrosis of the jaw; Ostéonécrose des maxillaires; Prise en charge; Recommandations; Surgery; Traitement conservateur